For decades, the story of Alzheimer’s research has been dominated by a battle between amyloid-beta and tau amyloids, both of which can kill neurons and impact the brain’s abil ...

Achieving good oral bioavailability for targeted protein degraders (TPDs) is vital in providing a patient-friendly way to ...

From theory to clinic, explore how molecular glue innovation is transforming targeted protein degradation for cancer and ...

Dry brushing is a mechanical exfoliation technique using a stiff, natural-fiber brush on dry skin, promoted for improved circulation and lymphatic flow. However, scientific evidence supporting health ...

Salarius also announces continued progress in its planned merger with Decoy Therapeutics Inc. (Decoy). Under the definitive agreement announced on January 13, 2025, Decoy will merge with a wholly ...

Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over ...

Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.

Astrazeneca AB has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to an interleukin-1 receptor-associated kinase 4 ...

Oxygen-Generating Transdermal Nanoplatform Codelivering BRD4 Proteolysis-Targeting Chimera/Verteporfin/CaO 2 Synergistically Remodels Immunosuppressive Melanoma Microenvironment to Potentiate ...

The EMBO Journal publishes papers describing original research of broad general interest in molecular and cell biology - a particular emphasis is placed on molecular mechanism and physiological ...

Cell Cycle; DNA Replication, Repair & Recombination; Post-translational Modifications, Proteolysis & Proteomics; Structural Biology Hartmut received his PhD from the University of Vienna for his work ...